To obtain a prolonged-action dosage form of Ketoprofen, a technique for delaying drug release from insoluble inert matrix of ethyl cellulose was evaluated. It was incorporated with excipients such as lactose, starch, hydroxy propyl methyl cellulose. influence of lubricants on release profiles was also investigated. The best result was obtained from the formula that consists of ethyl cellulose, lactose, starch, hydroxy propyl methyl cellulose, magnesium stearate, talc, aerosil (appropriate rate) and is coated with Eudragit L 100 (1mg/cm2)
Ketoprofen ; Cyclooxygenase Inhibitors ; tablets ; Pharmaceutical Preparations

A prospective study was conducted on 35 patients (22 men and 13 women) with atopic dermatitis at the H÷u NghÞ Hospital from March 15, 2000 to May 19, 2000. Age of patients ranged from 37 to 72. Control group included 30 individuals without history of this condition and had not any sign of atopic diseases at baseline. The results showed that Staphylococcus aureus colonized in the skin of most of atopic dermatitis patients (85.7%). The more severe the condition, the higher the rate. This bacterium colonized in 100% of patients who have discharge lesions and in 100% of patients who have severe condition. S. aureus has sensitivity of 100% with vancomycine, 96.6% with fucidic acid, 93.3% with gentamycin, 73.7% with cephalothin, 63.3% with oxacilline and 56.7% with erythromycin.
Dermatitis, Atopic ; Staphylococcus aureus

The total serum IgE level and blood eosinophil count were evaluated in 44 adult patients with atopic dermatitis and were compared with 13 healthy controls for IgE level, and with 31 healthy controls for eosinophil count. It is found that both mean of IgE levels (X+/-SD=1129.86+/-984.54 IU/mL) and absolute number of eosinophils (X+/-SD = 0.857+/-0.736 G/L) were significantly elevated in comparison with control groups (p<0.001). There was closed correlation between IgE level, eosinophil count and severity of disease (r=0.60, 0.58 respectively with p<0.01). There was weak correlation between IgE level and eosinophil count with r = 0.22.
Dermatitis, Atopic ; Eosinophils

This prospective study was designed to evaluate the major and minor features of Hanifin and Rajka in 100 adult patients with atopic dermatitis. The results showed that 65% of the patients had 4 major features and 80% had 6 minor features. The specific features included itchy (100%), chronic progress (100%), history of atopic conditions (79%), lichenification in flexural areas (78%), non-specific hand dermatitis (75%), onset before 5 years of age (74%), xerosis (63%). Non-specific features included the progress has been influenced by environmental and emotional factors (100%), white dermographism (79%). Uncommon features included Denie-Morgan folds (5%) and anterior neck folds (5%). Based on these results, a minimum clinical diagnostic criteria was proposed, by which to be diagnosed with atopic dermatitis, a patient must have itching plus 4 or more followed features: history of atopic conditions, lichenification in flexural areas or eczema on face in children under 10 years of age, chronic progress, non-specific hand dermatitis, onset before 5 years of age and xerosis.
Dermatitis, Atopic ; diagnosis ; adult

21 patients with the atopic dermatitis, ages of 49.1+/-15.7 (inpatient and outpatient) in Friendship hospital and the Central Institute of Dermatology and Venerology during 9/1997- 4/2000 participated to a study. The results have shown that the absolute amount of lymphocyte CD3, CD4, the ratio of CD4/CD8 and CD19 in patients with the atopic dermatitis were insignificant different from these in control group. The amount of CD were significantly reduced but not significantly increase the ratio of CD4/CD8. There was no relation between CD3, CD4, CD8, ratio of CD4/CD8 and CD 19 with the severity of disease.
Dermatitis, Atopic ; lymphocytes

We had studied in 60 patients with herpes zoster in Friendship Hospital and recognised that: men is 83.33%, women 16.67%, mean age was 65.42 ±7.18 mean duration of viral infection was 5.7 ±2.75 days. The sites most affected were thoracic (45%), cranial (23.4%), lumbar (15%), sacral (8.3%), and others (8.3%). We also used Acyclovir to treat 60 patients with zoster and found that: Acyclovir had good result in 89.47% and the vesibullar lesions with wet, red skin still remained in 10.53% patients. Side effects of Acyclovir were: diarrhea in 8.3%, nausea in 5% and vomiting in 3.3% patients. Acyclovir did not change renal and liver functions.
Herpes Zoster ; Aged ; Therapeutics ; Pharmaceutical Preparations ; Acyclovir

A study on 35 patients with the allergic dermatitis, ages of 41.23 treated in Friendship hospital during 5-7/2000 has shown that fucicort had a good effect in the first week and best in the second week. There was no adverse effects found. Patients tolerated well the drug.
Dermatitis, Allergic Contact ; therapy ; therapeutics

Background: Liver fibrosis is a common outcome of chronic liver disease and is primarily driven by hepatic stellate cell (HSC) activation. Irisin, a myokine released during physical exercise, is beneficial for metabolic disorders and mitochondrial dysfunction. This study aimed to explore the effects of irisin on liver fibrosis in HSCs, a bile duct ligation (BDL) mouse model, and the associated mitochondrial dysfunction. Methods: In vitro experiments utilized LX-2 cells, a human HSC line, stimulated with transforming growth factor-β1 (TGF-β1), a major regulator of HSC fibrosis, with or without irisin. Mitochondrial function was assessed using mitochondrial fission markers, transmission electron microscopy, mitochondrial membrane potential, and adenosine triphosphate (ATP) production. In vivo, liver fibrosis was induced in mice via BDL, followed by daily intraperitoneal injections of irisin (100 μg/kg/day) for 10 days. Results: In vitro, irisin mitigated HSC activation and reduced reactive oxygen species associated with the TGF-β1/Smad signaling pathway. Irisin restored TGF-β1-induced increases in fission markers (Fis1, p-DRP1) and reversed the decreased expression of TFAM and SIRT3. Additionally, irisin restored mitochondrial membrane potential and ATP production lowered by TGF-β1 treatment. In vivo, irisin ameliorated the elevated liver-to-body weight ratio induced by BDL and alleviated liver fibrosis, as evidenced by Masson’s trichrome staining. Irisin also improved mitochondrial dysfunction induced by BDL surgery. Conclusion Irisin effectively attenuated HSC activation, ameliorated liver fibrosis in BDL mice, and improved associated mitochondrial dysfunction. These findings highlight the therapeutic potential of irisin for the treatment of liver fibrosis.

Background: Liver fibrosis is a common outcome of chronic liver disease and is primarily driven by hepatic stellate cell (HSC) activation. Irisin, a myokine released during physical exercise, is beneficial for metabolic disorders and mitochondrial dysfunction. This study aimed to explore the effects of irisin on liver fibrosis in HSCs, a bile duct ligation (BDL) mouse model, and the associated mitochondrial dysfunction. Methods: In vitro experiments utilized LX-2 cells, a human HSC line, stimulated with transforming growth factor-β1 (TGF-β1), a major regulator of HSC fibrosis, with or without irisin. Mitochondrial function was assessed using mitochondrial fission markers, transmission electron microscopy, mitochondrial membrane potential, and adenosine triphosphate (ATP) production. In vivo, liver fibrosis was induced in mice via BDL, followed by daily intraperitoneal injections of irisin (100 μg/kg/day) for 10 days. Results: In vitro, irisin mitigated HSC activation and reduced reactive oxygen species associated with the TGF-β1/Smad signaling pathway. Irisin restored TGF-β1-induced increases in fission markers (Fis1, p-DRP1) and reversed the decreased expression of TFAM and SIRT3. Additionally, irisin restored mitochondrial membrane potential and ATP production lowered by TGF-β1 treatment. In vivo, irisin ameliorated the elevated liver-to-body weight ratio induced by BDL and alleviated liver fibrosis, as evidenced by Masson’s trichrome staining. Irisin also improved mitochondrial dysfunction induced by BDL surgery. Conclusion Irisin effectively attenuated HSC activation, ameliorated liver fibrosis in BDL mice, and improved associated mitochondrial dysfunction. These findings highlight the therapeutic potential of irisin for the treatment of liver fibrosis.

Background: Liver fibrosis is a common outcome of chronic liver disease and is primarily driven by hepatic stellate cell (HSC) activation. Irisin, a myokine released during physical exercise, is beneficial for metabolic disorders and mitochondrial dysfunction. This study aimed to explore the effects of irisin on liver fibrosis in HSCs, a bile duct ligation (BDL) mouse model, and the associated mitochondrial dysfunction. Methods: In vitro experiments utilized LX-2 cells, a human HSC line, stimulated with transforming growth factor-β1 (TGF-β1), a major regulator of HSC fibrosis, with or without irisin. Mitochondrial function was assessed using mitochondrial fission markers, transmission electron microscopy, mitochondrial membrane potential, and adenosine triphosphate (ATP) production. In vivo, liver fibrosis was induced in mice via BDL, followed by daily intraperitoneal injections of irisin (100 μg/kg/day) for 10 days. Results: In vitro, irisin mitigated HSC activation and reduced reactive oxygen species associated with the TGF-β1/Smad signaling pathway. Irisin restored TGF-β1-induced increases in fission markers (Fis1, p-DRP1) and reversed the decreased expression of TFAM and SIRT3. Additionally, irisin restored mitochondrial membrane potential and ATP production lowered by TGF-β1 treatment. In vivo, irisin ameliorated the elevated liver-to-body weight ratio induced by BDL and alleviated liver fibrosis, as evidenced by Masson’s trichrome staining. Irisin also improved mitochondrial dysfunction induced by BDL surgery. Conclusion Irisin effectively attenuated HSC activation, ameliorated liver fibrosis in BDL mice, and improved associated mitochondrial dysfunction. These findings highlight the therapeutic potential of irisin for the treatment of liver fibrosis.